Compare DexCom, Inc. (DXCM) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Target Corporation — how do they compare? DexCom, Inc. trades at $77.6 (market cap $28.06B), while Target Corporation trades at $140.41 (market cap $62.81B). The key difference: Target Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and Target Corporation pays a 3.36% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TGT | |
|---|---|---|
Market Cap | $28.06B | $62.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $141.19 |
52-Week Low | $54.84 | $83.68 |
Enterprise Value | $27.03B | $78.11B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Target (TGT) trades at $133.97, down 0.59% today, with a bullish technical outlook supported by moving averages. The company shows stable profitability with a 3.24% net margin and consistent earnings beats in recent quarters. Recent news highlights improving store traffic and merchandising momentum, while analyst consensus leans positive with a $137 price target.
The stock offers moderate upside potential driven by operational improvements and shareholder returns via dividends. Risks include competitive pressures and fluctuating consumer spending. Wall Street sentiment is balanced between buy and hold ratings, reflecting cautious optimism amid retail sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
